To evaluate efficacy, safety, changes in biological features, and quality of life (QoL) in low-risk anemic patients with MDS treated with darbepoetin alfa (DPO), 41 patients received DPO 150 μg weekly for 24 weeks. The dose was increased to 300 μg weekly in non-responsive patients. During treatment, 10/17 (59) transfusion-dependent (TD) and 13/23 (56) transfusion-free (TF) patients responded. In TF patients, Hb increased from 9.2±0.9g/dL to 10.3±1.4g/dL by 24 weeks (p0.004). The mean response duration was 22 weeks (95 CI: 19.724.0) in TF patients compared with 15.1 weeks (95 CI: 13.317.5) in TD patients. Response to treatment was associated with increases in QoL. Decreases in the percentage of apoptotic progenitor cells (p0.007) and CD34 cells (p0.005) were observed. These results confirm previous studies demonstrating the safety and efficacy of DPO in anemic patients with MDS. Biological changes and improvement in QoL were associated with response. Adequate dosing is to be determined. © 2010 Informa Healthcare USA, Inc.
Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: Efficacy and quality of life / Oliva, Esther N.; Francesco, Nobile; Alimena, Giuliana; Giorgina, Specchia; Marco, Danova; Bianca, Rovati; Francesca, Ronco; Stefana, Impera; Antonio, Risitano; Caterina, Alati; Breccia, Massimo; Ida, Carmosino; Iolanda, Vincelli; Roberto, Latagliata. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 51:6(2010), pp. 1007-1014. [10.3109/10428191003728610]
Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: Efficacy and quality of life
ALIMENA, Giuliana;Massimo Breccia;
2010
Abstract
To evaluate efficacy, safety, changes in biological features, and quality of life (QoL) in low-risk anemic patients with MDS treated with darbepoetin alfa (DPO), 41 patients received DPO 150 μg weekly for 24 weeks. The dose was increased to 300 μg weekly in non-responsive patients. During treatment, 10/17 (59) transfusion-dependent (TD) and 13/23 (56) transfusion-free (TF) patients responded. In TF patients, Hb increased from 9.2±0.9g/dL to 10.3±1.4g/dL by 24 weeks (p0.004). The mean response duration was 22 weeks (95 CI: 19.724.0) in TF patients compared with 15.1 weeks (95 CI: 13.317.5) in TD patients. Response to treatment was associated with increases in QoL. Decreases in the percentage of apoptotic progenitor cells (p0.007) and CD34 cells (p0.005) were observed. These results confirm previous studies demonstrating the safety and efficacy of DPO in anemic patients with MDS. Biological changes and improvement in QoL were associated with response. Adequate dosing is to be determined. © 2010 Informa Healthcare USA, Inc.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
